Molecular epidemiology and its current clinical use in cancer management

The Lancet Oncology

Volumn 11, Issue 4, 2010, Pages 383-390

  Hartman, Mikael ^a,b,c   Loy, En Yun ^a,b   Ku, Chee Seng ^a,b   Chia, Kee Seng ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; CLINICAL TRIAL; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN GENOME; MARKER GENE; MOLECULAR EPIDEMIOLOGY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMARKERS, PHARMACOLOGICAL; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MOLECULAR EPIDEMIOLOGY; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950308676     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70005-X     Document Type: Review

References (81)

1. Finishing the euchromatic sequence of the human genome. Nature 2004, 431:931-945.
2. Couzin J Genomics. New haplotype map may overhaul gene hunting. Science 2005, 310:601.
3. A haplotype map of the human genome. Nature 2005, 437:1299-1320.
4. Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
5. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
6. Manolio TA, Collins FS The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009, 60:443-456.
7. Chin L, Gray JW Translating insights from the cancer genome into clinical practice. Nature 2008, 452:553-563.
8. Collins FS, Barker AD Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 2007, 296:50-57.
9. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
10. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
11. Sotiriou C, Pusztai L Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
12. Clark GM Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr 2001, 30:17-21.
13. Frazer KA, Murray SS, Schork NJ, Topol EJ Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009, 10:241-251.
14. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009, 41:585-590.
15. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
16. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007, 39:352-358.
17. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40:316-321.
18. Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008, 40:1153-1155.
19. Hsu FC, Sun J, Wiklund F, et al. A novel prostate cancer susceptibility locus at 19q13. Cancer Res 2009, 69:2720-2723.
20. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008, 40:281-283.
21. Ghoussaini M, Song H, Koessler T, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008, 100:962-966.
22. Pharoah PD, Antoniou AC, Easton DF, Ponder BA Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358:2796-2803.
23. Schena M, Shalon D, Davis RW, Brown PO Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
24. Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D Light-directed, spatially addressable parallel chemical synthesis. Science 1991, 251:767-773.
25. van't Veer LJ, Bernards R Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452:564-570.
26. Esserman L, Shieh Y, Thompson I Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302:1685-1692.
27. Gail MH Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008, 100:1037-1041.
28. Hardy J, Singleton A Genomewide association studies and human disease. N Engl J Med 2009, 360:1759-1768.
29. Goldstein DB Common genetic variation and human traits. N Engl J Med 2009, 360:1696-1698.
30. Kraft P, Hunter DJ Genetic risk prediction-are we there yet?. N Engl J Med 2009, 360:1701-1703.
31. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
32. Lindstrom LS, Hall P, Hartman M, Wiklund F, Gronberg H, Czene K Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol 2007, 8:1001-1006.
33. Lindstrom LS, Hall P, Hartman M, Wiklund F, Czene K Is genetic background important in lung cancer survival?. PLoS ONE 2009, 4:e5588.
34. Hartman M, Lindstrom L, Dickman PW, Adami HO, Hall P, Czene K Is breast cancer prognosis inherited?. Breast Cancer Res 2007, 9:R39.
35. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000054.
36. Hunter KW Allelic diversity in the host genetic background may be an important determinant in tumor metastatic dissemination. Cancer Lett 2003, 200:97-105.
37. Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 2006, 24:4611-4619.
38. Ma XJ, Salunga R, Dahiya S, et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008, 14:2601-2608.
39. Weigelt B, Baehner FL, Reis-Filho JS The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010, 220:263-280.
40. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
41. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008, 100:1144-1154.
42. Sørlie T Molecular Classification of Breast Tumors Toward Improved Diagnostics and Treatments. Methods Mol Biol 2007, 360:91-114.
43. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007, 25:5187-5193.
44. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312-9318.
45. Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007, 96:2224-2231.
46. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436.
47. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007, 9:R7.
48. Tuma RS PARP inhibitors: will the new class of drugs match the hype?. J Natl Cancer Inst 2009, 101:1230-1232.
49. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. 2009 ASCO Annual Meeting, Orlando, FL, USA; May 29-June 2.
50. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. 2009 ASCO Annual Meeting, Orlando, FL, USA; May 29-June 2.
51. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. 2009 ASCO Annual Meeting, Orlando, FL, USA; May 29-June 2.
52. Ross RW, Oh WK, Xie W, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008, 26:842-847.
53. Febbo PG Genomic approaches to outcome prediction in prostate cancer. Cancer 2009, 115:3046-3057.
54. Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009, 301:393-403.
55. Koscielny S Critical review of microarray-based prognostic tests and trials in breast cancer. Curr Opin Obstet Gynecol 2008, 20:47-50.
56. Liu H, Liu W, Wu Y, et al. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 2005, 65:7635-7643.
57. Master SR, Mies C Gene-expression profiles and breast-cancer prognosis. Adv Anat Pathol 2003, 10:338-346.
58. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
59. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005, 23:732-740.
60. Chiuri VE, Leo G, Lorusso V Clinical and therapeutic perspectives of gene expression profiling for breast cancer. Ann Oncol 2007, 18(suppl 6):58-62.
61. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13:1198-1207.
62. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005, 11:5233-5240.
63. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-39.
64. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009, 27:2022-2029.
65. Correa Geyer F, Reis-Filho JS Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?. Int J Surg Pathol 2009, 17:285-302.
66. Nelson PS Predicting prostate cancer behavior using transcript profiles. J Urol 2004, 172:S28-S32.
67. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008, 371:29-40.
68. Bergh J Quo vadis with targeted drugs in the 21st century?. J Clin Oncol 2009, 27:2-5.
69. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
70. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555.
71. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65.
72. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006, 12:852-855.
73. Sawyers CL The cancer biomarker problem. Nature 2008, 452:548-552.
74. Simon R, Maitournam A Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004, 10:6759-6763.
75. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
76. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
77. Herman JG, Baylin SB Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
78. Fahrner JA, Eguchi S, Herman JG, Baylin SB Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002, 62:7213-7218.
79. Novak P, Jensen T, Oshiro MM, et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. Cancer Res 2006, 66:10664-10667.
80. Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009, 15:3881-3888.
81. Hitchins MP, Wong JJ, Suthers G, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007, 356:697-705.